Scientists continue to investigate how different receptor configurations contribute to distinct biological responses
Once treatment has started, we will monitor the patients progress throughout the course of treatment and make any necessary adjustments to the treatment plan
In the SMART trial, Semaglutide 2.4 mg reduced albuminuria in people with overweight or obesity and CKD without diabetes with 52% reduction in UACR
This scoping review aims to address this gap by exploring the effects of GLP-1 RAs across various psychiatric conditions, highlighting their therapeutic promise and the need for further investigation
First, cancer was not a primary endpoint in most included trials, which may have led to underreporting or misclassification
Adult use today rests on practitioner experience, published reviews, and pharmacokinetic (PK) studies, not large modern randomized controlled trials